<DOC>
	<DOCNO>NCT02579369</DOCNO>
	<brief_summary>This phase I/II open-label study evaluate efficacy safety ALLO-ASC-DFU patient Dystrophic Epidermolysis Bullosa .</brief_summary>
	<brief_title>Study Evaluate Safety ALLO-ASC-DFU Subjects With Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description>ALLO-ASC-DFU hydrogel sheet contain allogenic adipose-derived mesenchymal stem cell . Adipose-derived stem cell anti-inflammatory effect release growth factor vascular endothelial growth factor ( VEGF ) hepatocyte growth factor ( HGF ) , enhance wound heal regeneration new tissue , finally may provide new option treat Dystrophic Epidermolysis Bullosa .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<criteria>1 . Age : 10~60 2 . Diagnosed Dystrophic Epidermolysis Bullosa base immunofluorescence test . 3 . Bullous skin lesion size 10 cm^2 4 . Test negative Serum Î²HCG pregnancy test screening , subject fertile 5 . A subject willing follow protocol provide inform consent screening , give information respect clinical trial provide . 1 . A subject history epidermoid carcinoma within year screening . 2 . A subject require antibiotic due bacterial infection skin . 3 . A subject dose oral steroid , 0.5mg/kg day subject 18 , 20mg 2 week subject 18 , within 30 day prior screen . 4 . A subject treat radiotherapy immunosuppressant , within 30 day prior screen . 5 . A subject treat steroid locally , within 30 day prior screen . 6 . A subject 2times maximumstandardized value ALT , AST , ALP , bilirubin , total protein 7 . A subject 2times maximumstandardized value BUN , Creatinine 8 . A subject Albumin 2.0 g/dL . 9 . A subject Hemoglobin 6 g/dL ( anemic ) . 10 . A subject allergic response bovine derive protein fibrin glue . 11 . A subject administer biologic agent cell therapy , within 30 day prior screen . 12 . A subject administer stem cell treatment IV subcutaneously target wound , prior trial 13 . A subject enrol another clinical trial , within 30 day prior screen 14 . A subject serious disease affect clinical trial . 15 . A pregnant breastfeeding subject . 16 . A subject history drug abuse within 1 year clinical significance 17 . A subject proceed accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Epidermolysis Bullosa</keyword>
	<keyword>stem cell</keyword>
</DOC>